 |
 |
Read
more than 4,000 books online FREE! More than 1900 PDFs now available
for sale |
|
|
|
 |
|
Review of the Fialuridine (FIAU) Clinical Trials
|
|
Status: Available Now
Size: 280 pages, 8.5 x 11
Publication Year:1995
|
|
|
| Print |
List Price |
Your Price |
|
 |
PAPERBACK
ISBN-10: 0-309-05279-3
ISBN-13: 978-0-309-05279-5
|
$34.00 |
$30.60 |
Add to Cart |
|
Authors:
Frederick J. Manning and Morton Swartz, Editors; Committee to Review the Fialuridine (FIAU/FIAC) Clinical Trials, Institute of Medicine
Authoring Organizations
Description:
In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. ...
Read More |
|
|
Full Text
Jump to this book's table of contents to begin reading online for free.
|
Web Search Builder
Use this book's key terms to search within this book, across our
collection, or across the Web.
Reference
Finder
Paste in your own text to find books that relate to your topic.
|
|
Description
In June 1993 a clinical trial of fialuridine (FIAU), a promising new medication for hepatitis B, was abruptly terminated when one of the 15 out-patients participating in the National Institutes of Health (NIH) study was suddenly hospitalized with liver failure. Although all the remaining patients were contacted and told to stop taking their medication, six more subsequently developed severe toxicity. Five patients died, and two others were probably saved from death only by having liver transplants. In response to a request from the Secretary of the Department of Health and Human Services, the IOM committee has analyzed the FIAU clinical trials, making recommendations for additional safeguards for the conduct of future clinical trials. This evaluation included the review of documents pertaining to investigational new drug submissions, protocols and consent forms from other clinical trials, as well as information available from other clinical and preclinical experience with compounds related to FIAU and its parent drug, fiacitibine (FIAC), which is metabolized to FIAU. The committee does not seek to affix responsibility for the adverse outcome of this NIH trial, but instead focuses on whether any rules or procedures governing the clinical trials process itself need to be changed, and if so, what burdens or costs such changes might place on future clinical trials.
About the PDF: What am I Buying?
About Our PDFs
This book can be purchased as a computer file. The format of the file is called a "PDF". To open, view and print the file, you must have third party software (e.g. Adobe Reader or XPDF) installed on your computer.
Benefits of Buying a PDF
-
Instant. Buy it, download it immediately, and start reading.
-
Convenient. Download it to your laptop and read it whenever, wherever.
-
Searchable. Search for any word or phrase.
What are my options?
| If you want ...
| Then ...
|
| ... a computer file containing the entire book |
... buy a PDF |
| ... to read the book immediately and also own a copy for your bookshelf |
... buy the bundle |
| ... a copy for your bookshelf |
... buy the book |
Will my PDF be emailed to me?
No. After buying the PDF, we will email you instructions on how to download the file from our Web site. The PDF file will not be emailed to you.
See our Frequently Asked Questions for more information including:
|
SIGN UP FOR...
 New Title Emails
Read about the newest releases and receive special offers.
|
|
|
Items in cart [0]